359 related articles for article (PubMed ID: 3260814)
41. Effect of isotype on internalization and cytotoxicity of CD19-ricin A immunotoxins.
van Oosterhout YV; van den Herik-Oudijk IE; Wessels HM; de Witte T; van de Winkel JG; Preijers FW
Cancer Res; 1994 Jul; 54(13):3527-32. PubMed ID: 7516821
[TBL] [Abstract][Full Text] [Related]
42. Specific killing of human T-leukemia cells by immunotoxins prepared with ricin A chain and monoclonal anti-human T-cell leukemia antibodies.
Seon BK
Cancer Res; 1984 Jan; 44(1):259-64. PubMed ID: 6606488
[TBL] [Abstract][Full Text] [Related]
43. Sensitivity of target cells to immunotoxins: possible role of cell-surface antigens.
Colombatti M; Bron C
Immunology; 1985 Jun; 55(2):331-8. PubMed ID: 2861156
[TBL] [Abstract][Full Text] [Related]
44. Cytotoxicity of streptavidin-blocked biotinyl-ricin is retrieved by in vitro immunotargeting via biotinyl monoclonal antibody.
Schechter B; Arnon R; Wilchek M
Cancer Res; 1992 Aug; 52(16):4448-52. PubMed ID: 1643636
[TBL] [Abstract][Full Text] [Related]
45. An assay that predicts the ability of monoclonal antibodies to form potent ricin A chain-containing immunotoxins.
Till M; May RD; Uhr JW; Thorpe PE; Vitetta ES
Cancer Res; 1988 Mar; 48(5):1119-23. PubMed ID: 3257712
[TBL] [Abstract][Full Text] [Related]
46. Covalent binding of human alpha 2-macroglobulin to deglycosylated ricin A chain and its immunotoxins.
Ghetie MA; Uhr JW; Vitetta ES
Cancer Res; 1991 Mar; 51(5):1482-7. PubMed ID: 1705175
[TBL] [Abstract][Full Text] [Related]
47. Monoclonal antibodies recognising the cluster 2 antigen associated with human small cell lung cancer mediate the toxic effects of ricin A chain in an indirect assay of immunotoxin cytotoxicity.
Derbyshire EJ; Wawrzynczak EJ
Br J Cancer Suppl; 1991 Jun; 14():74-7. PubMed ID: 1645578
[TBL] [Abstract][Full Text] [Related]
48. Bispecific anti-CD22/anti-CD3-ricin A chain immunotoxin is cytotoxic to Daudi lymphoma cells but not T cells in vitro and shows both A-chain-mediated and LAK-T-mediated killing.
Shen GL; Li JL; Vitetta ES
J Immunol; 1994 Mar; 152(5):2368-76. PubMed ID: 8133047
[TBL] [Abstract][Full Text] [Related]
49. Elimination of clonogenic T-leukemic cells from human bone marrow using anti-Mr 65,000 protein immunotoxins.
Stong RC; Youle RJ; Vallera DA
Cancer Res; 1984 Jul; 44(7):3000-6. PubMed ID: 6372999
[TBL] [Abstract][Full Text] [Related]
50. Antidisialoganglioside ricin A-chain immunotoxins show potent antitumor effects in vitro and in a disseminated human neuroblastoma severe combined immunodeficiency mouse model.
Gottstein C; Schön G; Tawadros S; Kube D; Wargalla-Plate UC; Hansmann ML; Wacker HH; Berthold F; Diehl V; Engert A
Cancer Res; 1994 Dec; 54(23):6186-93. PubMed ID: 7954465
[TBL] [Abstract][Full Text] [Related]
51. [Preparation of an anti-human immunotoxin against bladder carcinoma and its in vitro targeting cytotoxicity].
Zhao C
Zhonghua Zhong Liu Za Zhi; 1992 Mar; 14(2):109-11. PubMed ID: 1618077
[TBL] [Abstract][Full Text] [Related]
52. Targeted cancer therapy: conferring specificity to cytotoxic drugs.
Chari RV
Acc Chem Res; 2008 Jan; 41(1):98-107. PubMed ID: 17705444
[TBL] [Abstract][Full Text] [Related]
53. Antigenic modulation by anti-CD5 immunotoxins.
Manske JM; Buchsbaum DJ; Azemove SM; Hanna DE; Vallera DA
J Immunol; 1986 Jun; 136(12):4721-8. PubMed ID: 3086441
[TBL] [Abstract][Full Text] [Related]
54. Toxicity of a monoclonal F(ab')2:ricin A conjugate for retinoblastoma in vitro.
Merriam JC; Lyon HS; Char DH
Cancer Res; 1984 Aug; 44(8):3178-83. PubMed ID: 6744258
[TBL] [Abstract][Full Text] [Related]
55. Ricin A immunotoxins of IgG and Fab of anti-CALLA monoclonal antibody: effect of water soluble long-chain SPDP on conjugate yield, immunoselectivity and cytotoxicity.
Woo BH; Lee JT; Lee KC
Arch Pharm Res; 1994 Dec; 17(6):452-7. PubMed ID: 10319157
[TBL] [Abstract][Full Text] [Related]
56. Selective killing of human bladder cancer cells by combined treatment with A and B chain ricin antibody conjugates.
Thiesen HJ; Juhl H; Arndt R
Cancer Res; 1987 Jan; 47(2):419-23. PubMed ID: 3539323
[TBL] [Abstract][Full Text] [Related]
57. Sensitivity and selectivity of ricin toxin A chain-monoclonal antibody 791T/36 conjugates against human tumor cell lines.
Embleton MJ; Byers VS; Lee HM; Scannon P; Blackhall NW; Baldwin RW
Cancer Res; 1986 Nov; 46(11):5524-8. PubMed ID: 3489523
[TBL] [Abstract][Full Text] [Related]
58. Targeted anti-tumor agents and their cytotoxicity on gastric cancer cells in vitro.
Li S; Zhang XY; Chen XT; Fan DM; Tan LS; Pan HZ; Huang LQ
Chin Med J (Engl); 1990 May; 103(5):376-9. PubMed ID: 2118053
[TBL] [Abstract][Full Text] [Related]
59. Comparison of two anti-Thy 1.1-abrin A-chain immunotoxins prepared with different cross-linking agents: antitumor effects, in vivo fate, and tumor cell mutants.
Thorpe PE; Blakey DC; Brown AN; Knowles PP; Knyba RE; Wallace PM; Watson GJ; Wawrzynczak EJ
J Natl Cancer Inst; 1987 Nov; 79(5):1101-12. PubMed ID: 2890786
[TBL] [Abstract][Full Text] [Related]
60. Cytotoxic activity of disulfide-stabilized recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) toward fresh malignant cells from patients with B-cell leukemias.
Kreitman RJ; Margulies I; Stetler-Stevenson M; Wang QC; FitzGerald DJ; Pastan I
Clin Cancer Res; 2000 Apr; 6(4):1476-87. PubMed ID: 10778980
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
